7 4 • O U T PA T I E N T S U R G E R Y M A G A Z I N E • N O V E M B E R 2 0 1 8
What's New in Cataract Medications
A look at 6 new drugs your surgeons might want to try.
Dan O'Connor | Editor-in-Chief
I
n cataract surgery, there's a drug for that. For dropless and for
sutureless. For pre-op sedation and for pupil dilation. And, of
course, for pain. Here's a review of 6 relatively new medications
your eye doctors might soon want to use. In alphabetical order:
Dextenza, Dexycu, Inveltys, MKO Melt, Omidria and ReSure Sealant.
Dextenza
Dextenza (dexametha-
sone insert) 0.4mg is a
corticosteroid intra-
canalicular insert that
the surgeon places
through the punctum
into the canaliculus to
treat ocular pain. It's
designed to deliver a
tapered dose of dex-
amethasone to the
ocular surface for up to 30 days without preservatives, says Ocular
Therapeutix. Following treatment, Dextenza is intended to resorb and
exit the nasolacrimal system without the need for removal.
Dextenza has completed Phase 3 evaluation for the treatment of
ocular pain and inflammation following ophthalmic surgery, but is cur-
rently limited to investigational use only.
Dexycu
Dexycu (dexamethasone intraocular suspension) 9% is an extended-
• PUNCTUM PAIN INSERT Dextenza (dexamethasone insert) 0.4mg is a corticosteroid
intracanalicular insert placed through the punctum for the treatment of ocular pain and
inflammation following ophthalmic surgery.
Ocular
Therapeutix